Cybin is trading at $12.97 (-5.39%) amid broader risk-off conditions.
- On September 23, 2026, the Nasdaq was down 0.94% and the S&P 500 was down 0.55%.
- No new company-specific negative announcement was identified. The scheduled CEO fireside chat had no reported clinical, financial, regulatory, or corporate update; HLP003 presentations were announced previously.
- Biotech outperformed broader markets, making sector weakness a less likely explanation.